Study of Ataluren (PTC124) in Hemophilia A and B

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 14, 2009

Primary Completion Date

August 30, 2011

Study Completion Date

August 30, 2011

Conditions
Hemophilia AHemophilia B
Interventions
DRUG

Ataluren

Oral powder

Trial Locations (13)

19104

Children's Hospital of Philadelphia, Philadelphia

37232

Vanderbilt Hemostatis and Thrombosis Clinic, Nashville

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46260

St. Vincent Indianapolis Hospital, Indianapolis

61614

The Bleeding and Clotting Disorders Institute, Peoria

98104

Puget Sound Blood Center, Seattle

01605

New England Hemophilia Center, Worcester

V6Z 1Y6

St. Paul's Hospital, Vancouver

Unknown

Hôpital Cardiologique, Lille

Hôpital Edouard Herriot, Lyon

Hôpital Necker Enfants Malades, Paris

Azienda Ospedaliero-Universitaria Careggi Viale G.B. Morgagni, Florence

A.Bianchi Bonomi Hemophilia and Thrombosis Center, Milan

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

PTC Therapeutics

INDUSTRY